Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by ADAR1 Capital Management LLC

ADAR1 Capital Management LLC decreased its stake in shares of Royalty Pharma plc (NASDAQ:RPRX) by 95.4% during the 4th quarter, HoldingsChannel.com reports. The firm owned 49,963 shares of the biopharmaceutical company’s stock after selling 1,046,703 shares during the quarter. ADAR1 Capital Management LLC’s holdings in Royalty Pharma were worth $1,275,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of RPRX. Swedbank AB lifted its holdings in Royalty Pharma by 10.3% in the fourth quarter. Swedbank AB now owns 12,164,170 shares of the biopharmaceutical company’s stock worth $310,308,000 after acquiring an additional 1,136,800 shares during the last quarter. State Street Corp boosted its holdings in shares of Royalty Pharma by 0.3% during the third quarter. State Street Corp now owns 9,516,262 shares of the biopharmaceutical company’s stock valued at $269,215,000 after acquiring an additional 29,451 shares during the period. Geode Capital Management LLC lifted its position in Royalty Pharma by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 7,312,551 shares of the biopharmaceutical company’s stock valued at $186,846,000 after purchasing an additional 46,765 shares during the last quarter. Norges Bank acquired a new stake in Royalty Pharma in the 4th quarter valued at approximately $124,498,000. Finally, Charles Schwab Investment Management Inc. boosted its position in Royalty Pharma by 4.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 3,131,628 shares of the biopharmaceutical company’s stock worth $79,888,000 after acquiring an additional 130,025 shares during the period. 54.35% of the stock is owned by institutional investors.

Royalty Pharma Price Performance

Shares of RPRX stock opened at $31.11 on Monday. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64. Royalty Pharma plc has a 12-month low of $24.05 and a 12-month high of $34.20. The firm has a fifty day moving average of $32.52 and a 200-day moving average of $28.97. The firm has a market capitalization of $17.93 billion, a price-to-earnings ratio of 21.46, a price-to-earnings-growth ratio of 2.31 and a beta of 0.50.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. On average, equities research analysts forecast that Royalty Pharma plc will post 4.49 earnings per share for the current year.

Royalty Pharma Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 10th. Stockholders of record on Friday, February 21st were paid a dividend of $0.22 per share. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.21. This represents a $0.88 annualized dividend and a dividend yield of 2.83%. The ex-dividend date of this dividend was Friday, February 21st. Royalty Pharma’s dividend payout ratio (DPR) is currently 60.69%.

Analysts Set New Price Targets

RPRX has been the subject of a number of research analyst reports. TD Cowen raised shares of Royalty Pharma to a “strong-buy” rating in a research note on Tuesday, December 24th. Citigroup reaffirmed a “buy” rating on shares of Royalty Pharma in a research note on Friday, March 28th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $41.60.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.